Oral Peroxisome Proliferator–Activated Receptor-α Agonist Enhances Corneal Nerve Regeneration in Patients With Type 2 Diabetes
Diabetes · 01.07.2023 · 72 (7) · 932-946
DOI: 10.2337/db22-0611 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, online erschienen am 29.11.2022. Verfasst von Calesta Hui Yi Teo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Fenofibrate, Diabetic Neuropathies. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Singapore National Medical Research Council.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Diabetic corneal neuropathy (DCN) is a common complication of diabetes. However, there are very limited therapeutic options. We investigated the effects of a peroxisome proliferator–activated receptor-α (PPAR-α) agonist, fenofibrate, on 30 patients (60 eyes) with type 2 diabetes. On in vivo confocal microscopy evaluation, there was significant stimulation of corneal nerve regeneration and a reduction in nerve edema after 30 days of oral fenofibrate treatment, as evidenced by significant improvement in corneal nerve fiber density (CNFD) and corneal nerve fiber width, respectively. Corneal epithelial cell morphology also significantly improved in cell circularity. Upon clinical examination, fenofibrate significantly improved patients’ neuropathic ocular surface status by increasing tear breakup time along with a reduction of corneal and conjunctival punctate keratopathy. Tear substance P (SP) concentrations significantly increased after treatment, suggesting an amelioration of ocular surface neuroinflammation. The changes in tear SP concentrations was also significantly associated with improvement in CNFD. Quantitative proteomic analysis demonstrated that fenofibrate significantly upregulated and modulated the neurotrophin signaling pathway and linolenic acid, cholesterol, and fat metabolism. Complement cascades, neutrophil reactions, and platelet activation were also significantly suppressed. Our results showed that fenofibrate could potentially be a novel treatment for patients with DCN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Tissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore.
- Ocular Proteomic Group, Singapore Eye Research Institute, Singapore.
- Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore.
- Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Department of Pharmacy, National University of Singapore, Singapore.
ORCID-Profile: Calesta Hui Yi Teo, Yu-Chi Liu
Förderung
- Singapore National Medical Research Council
Zitieren
APA
Teo, C. H. Y., Lin, M. T., Lee, I. X. Y., Koh, S. K., Zhou, L., Goh, D. S., Choi, H., Koh, H. W. L., Lam, A. Y. R., Lim, P. S., Mehta, J. S., Kovalik, J. P., Coffman, T. M., Tan, H. C., & Liu, Y. C. (2023). Oral Peroxisome Proliferator–Activated Receptor-α Agonist Enhances Corneal Nerve Regeneration in Patients With Type 2 Diabetes. Diabetes, 72(7), 932-946. https://doi.org/10.2337/db22-0611
Vancouver
Teo CHY, Lin MT, Lee IXY, Koh SK, Zhou L, Goh DS, et al. Oral Peroxisome Proliferator–Activated Receptor-α Agonist Enhances Corneal Nerve Regeneration in Patients With Type 2 Diabetes. Diabetes. 2023;72(7):932-946. doi:10.2337/db22-0611
BibTeX
@article{Teo2023,
author = {Teo, Calesta Hui Yi and Lin, Molly Tzu-Yu and Lee, Isabelle Xin Yu and Koh, Siew-Kwan and Zhou, Lei and Goh, Dylan Shaoying and Choi, Hyungwon and Koh, Hiromi Wai Ling and Lam, Amanda Yun Rui and Lim, Paik Shia and Mehta, Jodhbir S and Kovalik, Jean-Paul and Coffman, Thomas M and Tan, Hong Chang and Liu, Yu-Chi},
title = {Oral Peroxisome Proliferator–Activated Receptor-α Agonist Enhances Corneal Nerve Regeneration in Patients With Type 2 Diabetes},
journal = {Diabetes},
year = {2023},
volume = {72},
number = {7},
pages = {932--946},
doi = {10.2337/db22-0611}
}
EUVIMED